Esophageal Cancer-Pipeline Review H2 2018

Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer-Pipeline Review, H2 2018, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Get sample copy of report at: https://www.reportsweb.com/inquiry&RW00012265442/sample
The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 46, 45, 3, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 3 and 2 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Enquire about report at: https://www.reportsweb.com/inquiry&RW00012265442/buying
Scope
-The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
-The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

ReportsWeb is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.

533, 5th floor, Amanora Township,
Amanora Chambers, East Block,
Kharadi Road, Hadapsar, Pune-411028
Call: +1-646-491-9876
Email: sales@reportsweb.com

This release was published on openPR.